Market Overview

UPDATE: Piper Jaffray Lowers PT on Forest to $27

Related FRX
Icahn's (Potential) Move Into Biotech
Carl Icahn's Track Record In Big Pharma

Piper Jaffray reiterates an Underweight rating on Forest Laboratories (NYSE: FRX) and decreases its price target from $28 to $27.

Piper Jaffray notes, “Not surprisingly, management pointed to heavy additional SG&A spending on tap to support new launches, namely linaclotide for constipation predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation (CIC), and aclidinium for chronic obstructive pulmonary disease (COPD). With new products like linaclotide, aclidinium, and Daliresp facing significant adoption risks in our view and given that FRX's profitability for the foreseeable future is coming mainly from declining assets (i.e. Lexapro and Namenda), we continue to believe that FRX shares are expensive with a FY 2014 P/E of 21x. We reiterate our Underweight rating and are lowering our PT to $27 from $28 (reflecting lower Lexapro and Viibryd estimates).”

Forest Laboratories closed at $34.57 on Wednesday.

Latest Ratings for FRX

May 2014UBSMaintainsNeutral
Apr 2014Cantor FitzgeraldMaintainsHold
Apr 2014SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for FRX
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (FRX)

View Comments and Join the Discussion!

Partner Center